Evidence map›Paper›PMID 30362914›Full record

ArticleJournal of managed care & specialty pharmacy2018

An Innovative Approach to Improving the Proposed CMS Star Rating "Statin Use in Persons with Diabetes".

Thomas Vanderholm, Hannah M Renner, Samuel F Stolpe, Alex J Adams

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Pharmacist Prescriptive Authority: Lessons from Idaho.Pharmacy (Basel, Switzerland) · 2020
    Article
  3. Article
  4. Article
  5. Regulating pharmacist services: Achieving a full scope of practice.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas Vanderholm1 Washington State University, Spokane.
Hannah M Renner2 Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.
Samuel F Stolpe3 Scientific Technology Corporation, San Francisco, California.
Alex J Adams4 Idaho State Board of Pharmacy, Boise.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Statin Use in Persons with Diabetes (SUPD) measure has been adopted by the Centers for Medicare and Medicaid Services as a display measure for Medicare Part C and Part D plan sponsors and is slated for inclusion within the primary star rating measure set. As such, the measure has become a focal point for quality improvement efforts by many health plans. Current pharmacy-based interventions reported in the literature involve pharmacists recommending that a patient's provider issue a prescription for a statin; studies to date have not shown that this intervention has been effective for the majority of patients with diabetes. One innovative option is pharmacist prescriptive authority of statins for patients with diabetes. In such a model, a pharmacist identifies a patient with diabetes who is not on a statin, assesses the patient for contraindications and appropriateness of therapy, and works directly with the patient to close the gap in care. This solution could lead to earlier initiation of statin therapy and reduce the burdens associated with multiple communications with the patient's primary care provider. In 2018, Idaho became the first state to allow pharmacist prescribing to close the SUPD measure, with certain regulatory safeguards in place. DISCLOSURES: No funding supported the writing of this article. The authors have nothing to disclose.

Indexed as

AdultAgedAtherosclerosisCenters for Medicare and Medicaid Services, U.S.Diabetes ComplicationsDrug PrescriptionsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLegislation, PharmacyMedication Therapy ManagementMiddle AgedPharmacistsQuality ImprovementQuality Indicators, Health CareUnited StatesHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID30362914
PMCPMC10398108

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.